Skip to content

Summit Therapeutics SMMT Grant — Grant income

Discontinued — last reported Q3 '20

Similar metrics at other companies

Moderna logo
MRNAGrant revenue — Total Revenue
$0-100%
Universal Health Services logo
UHSGrant — Revenue
$2.11M-83.7%
Cytokinetics logo
CYTKResearch And Development Milestone Grant And Other Revenues Net — Revenue
$0
Cytokinetics logo
CYTKResearch And Development Grant And Other Revenues Net — Revenue
$6.59M+477%
Moderna logo
MRNAGrant revenue — Additions
$8M+300%
Moderna logo
MRNAGrant revenue — Contract With Customer, Liability, Deductions During Period
$1M

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.

The official record: Summit Therapeutics’s 10-Q, filed November 16, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does grant — grant income mean?
Revenue earned from external research grants and government funding to support drug development activities.
How do you interpret grant — grant income?
An increase suggests successful procurement of non-dilutive capital and external validation of the research pipeline, while a decrease may indicate a reduction in external funding support or the completion of specific grant-funded projects.
How does grant — grant income compare across companies?
Common among early-stage biopharmaceutical companies, where grant income is often compared against total R&D expenses to assess the degree of external funding support for the clinical pipeline.